



**Ephrata  
Community  
Hospital**

J-2

169 Martin Avenue • P.O. Box 1002 • Ephrata, PA 17522-1002 • (717) 733-0311 • Fax (717) 733-0876  
www.ephratahospital.org

December 1, 2006

377-17125-01

03012241

Licensing Branch  
Nuclear Materials Safety Section  
Division of Safety & Safeguards  
U.S. N.R.C. - Region I  
475 Allendale Rd.  
King of Prussia, PA 19406

Dear License Reviewer,

Please remove the following physician from our list of Authorized Users for 10 CFR 35.100 and 35.200 materials. He no longer performs licensed activities at our facility.

**George A. Crawford, M.D.**

Please add the following physician to our license as an Authorized User for the material categories listed. A copy of his A.B.R. certificate is enclosed.

10 CFR 35.100 and 35.200 materials:

**John C. Nawa, M.D.**

Additionally, please change your Ephrata Community Hospital Administrative Representative from Robert F. Graupensperger to John N. Snader. All future correspondence should be sent to John Snader.

Our N.R.C. license no. is # 37-17125-01 (Ephrata Community Hospital).

Sincerely,

John N. Snader  
Vice President for Ancillary Services

139790  
NMSS/RGNI MATERIALS-C02

C. Douglas Maynard, M.D., *President*  
Winston-Salem, North Carolina

Lester J. Peters, M.D., *Vice President*  
Houston, Texas

William J. Casarella, M.D., *Secretary-Treasurer*  
Atlanta, Georgia

David C. Binnig, M.D.  
Salt Lake City, Utah

Robert E. Campbell, M.D.  
Philadelphia, Pennsylvania

Edward L. Chaney, Ph.D.  
Chapel Hill, North Carolina

Lawrence W. Davis, M.D.  
Atlanta, Georgia

Gerald D. Dodd, M.D.  
Houston, Texas

Sarah S. Donaldson, M.D.  
Stanford, California

Milton Elkin, M.D.  
New York, New York

Thomas S. Hanft, M.D.  
Houston, Texas

# The American Board of Radiology

**M. Paul Capp, M.D., Executive Director**

*Associate Executive Director*  
Kenneth L. Krabbenhoft, M.D.

*Assistant Executive Directors*  
Robert S. Campbell, M.D., *Diagnostic Radiology*  
Lawrence W. Davis, M.D., *Radiation Oncology*

5255 E. WILLIAMS CIRCLE, SUITE 6800  
TUCSON, ARIZONA 85711

PHONE (520) 790-2900  
FAX (520) 790-3200

June 7, 1995

David H. Hussey, M.D.  
Iowa City, Iowa

George R. Leopold, M.D.  
San Diego, California

Rodney R. Millson, M.D.  
Gainesville, Florida

Carlos A. Perez, M.D.  
St. Louis, Missouri

Andrew K. Poznanski, M.D.  
Chicago, Illinois

Melen C. Redman, M.D.  
Dallas, Texas

Len F. Rogers, M.D.  
Chicago, Illinois

Joseph F. Sackett, M.D.  
Madison, Wisconsin

Isaac Sanders, M.D.  
Los Angeles, California

Melvyn H. Schreiber, M.D.  
Calverton, Texas

James E. Youker, M.D.  
Milwaukee, Wisconsin

39827 DR 02 124  
JOHN CHARLES NAWA MD  
403 ANN STREET  
WEST READING, PA 19611

Dear Doctor Nawa:

I am pleased to inform you that you passed the June 1995 oral examination, and The American Board of Radiology grants you its certificate in DIAGNOSTIC RADIOLOGY.

A certificate will be sent to you when we have received verification from your Program Director that you have fulfilled all training requirements. The certificate will be sent via UPS to the above address in approximately three months. Your name will appear on the certificate as listed above. If you wish your name to appear differently, please forward a postcard to the Board office indicating your preference no later than June 30, 1995.

Your name will be included in a Directory published by the American Board of Medical Specialties unless you specify otherwise in writing to the ABMS. It is your responsibility to notify your local and state medical organizations of your certification.

As a Diplomate of The American Board of Radiology, you should be advised of the following additional certifications available to you. Training and practice requirements for these additional fields of certification may be obtained from the ABR office.

Diagnostic Radiology with Special Competence in Nuclear Radiology;  
Diagnostic Radiology with Added Qualifications in Pediatric Radiology;  
Diagnostic Radiology with Added Qualifications in Vascular and Interventional Radiology;  
Diagnostic Radiology with Added Qualifications in Neuroradiology.

With personal congratulations, I am

Sincerely,



M. Paul Capp, M.D.

MPC:mk

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES  
Amendment No. 15

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Ephrata Community Hospital</p> <p>2. 169 Martin Avenue Ephrata, Pennsylvania 17522</p>	<p>In accordance with the letter dated July 22, 2002,</p> <p>3. License number 37-17125-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2012</p> <hr/> <p>5. Docket No. 030-12241 Reference No.</p>
--	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Strontium 89	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 50 millicuries
D. Samarium 153	D. Any radiopharmaceutical identified in 10 CFR 35.300	D. 1000 millicuries

9. Authorized use:
- A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
  - B. Any imaging and localization procedure approved in 10 CFR 35.200.
  - C. and D. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.

**CONDITIONS**

10. Licensed material may be used only at the licensee's facilities located at 169 Martin Avenue, Ephrata, Pennsylvania.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 3 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-17125-01

Docket or Reference Number  
030-12241

Amendment No. 15

11. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the materials and uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Robert J. Brosbe, M.D.	35.100; 35.200
John C. Nawa, M.D.	35.100; 35.200
Jang K. Oh, M.D.	35.100; 35.200
Carol Wirth, M.D.	35.100; 35.200
Kenneth M. Neigut, M.D.	35.100; 35.200
Anthony J. Giordano, M.D.	35.100; 35.200
Michael L. Sacherik, M.D.	35.100; 35.200
Michael Lambo, M.D.	Strontium 89 and Samarium 153 for procedures approved in 10 CFR 35.300

12. The Radiation Safety Officer for this license is Robert J. Brosbe, M.D.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material so that at no time is a quantity of radioactive material possessed in excess of a quantity which requires decommissioning funding in accordance with 10 CFR 30.35(d), 10 CFR 40.36(b), or 10 CFR 70.25(d).

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 3 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
37-17125-01Docket or Reference Number  
030-12241

Amendment No. 15

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received December 30, 1991
  - B. Letter dated April 25, 1992
  - C. Letter dated June 15, 1992
  - D. Letter dated July 14, 1992
  - E. Letter dated January 12, 2001
  - F. Letter dated July 22, 2002

For the U.S. Nuclear Regulatory Commission

*Original signed by Tara L. Weidner*Date October 18, 2002

By

Tara L. Weidner  
Nuclear Materials Safety Branch 1  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406